Magali van den Kerkhof
Overview
Explore the profile of Magali van den Kerkhof including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zheng Y, van den Kerkhof M, Ibrahim M, de Esch I, Maes L, Sterk G, et al.
J Med Chem
. 2024 Feb;
67(4):2849-2863.
PMID: 38330051
Human African trypanosomiasis (HAT) still faces few therapeutic options and emerging drug resistance, stressing an urgency for novel antitrypanosomal drug discovery. Here, we describe lead optimization efforts aiming at improving...
2.
Zheng Y, van den Kerkhof M, van der Meer T, Gul S, Kuzikov M, Ellinger B, et al.
J Med Chem
. 2023 Jul;
66(15):10252-10264.
PMID: 37471520
Human African Trypanosomiasis (HAT), caused by , is one of the neglected tropical diseases with a continuing need for new medication. We here describe the discovery of 5-phenylpyrazolopyrimidinone analogs as...
3.
Mowbray C, Braillard S, Glossop P, Whitlock G, Jacobs R, Speake J, et al.
J Med Chem
. 2021 Oct;
64(21):16159-16176.
PMID: 34711050
Visceral leishmaniasis (VL) is a parasitic disease endemic across multiple regions of the world and is fatal if untreated. Current therapies are unsuitable, and there is an urgent need for...
4.
Bulte D, Van Bockstal L, Dirkx L, van den Kerkhof M, De Trez C, Timmermans J, et al.
PLoS Negl Trop Dis
. 2021 Jul;
15(7):e0009622.
PMID: 34292975
Background: Miltefosine (MIL) is currently the only oral drug available to treat visceral leishmaniasis but its use as first-line monotherapy has been compromised by an increasing treatment failure. Despite the...
5.
van den Kerkhof M, Leprohon P, Mabille D, Hendrickx S, Tulloch L, Wall R, et al.
Microorganisms
. 2021 Jul;
9(7).
PMID: 34210040
Current treatment options for visceral leishmaniasis have several drawbacks, and clinicians are confronted with an increasing number of treatment failures. To overcome this, the Drugs for Neglected Diseases (DND) has...
6.
van den Kerkhof M, Sterckx Y, Leprohon P, Maes L, Caljon G
Microorganisms
. 2020 Jul;
8(6).
PMID: 32599761
Kinetoplastids are the causative agents of leishmaniasis, human African trypanosomiasis, and American trypanosomiasis. They are responsible for high mortality and morbidity in (sub)tropical regions. Adequate treatment options are limited and...
7.
Van Bockstal L, Bulte D, van den Kerkhof M, Dirkx L, Mabille D, Hendrickx S, et al.
Front Immunol
. 2020 Jun;
11:1113.
PMID: 32582193
Type I interferons (IFNs) induced by an endogenous RNA virus or exogenous viral infections have been shown to exacerbate infections with New World Cutaneous parasites, however, the impact of type...
8.
Eberhardt E, Hendrickx R, van den Kerkhof M, Monnerat S, Alves F, Hendrickx S, et al.
J Microbiol Methods
. 2020 May;
173:105935.
PMID: 32376283
Background: Molecular detection techniques using peripheral blood are preferred over invasive tissue aspiration for the diagnosis and post-treatment follow-up of visceral leishmaniasis (VL) patients. This study aims to identify suitable...
9.
Eberhardt E, Bulte D, Van Bockstal L, van den Kerkhof M, Cos P, Delputte P, et al.
J Antimicrob Chemother
. 2018 Nov;
74(2):395-406.
PMID: 30412253
Objectives: Miltefosine is currently the only oral drug for visceral leishmaniasis, and although deficiency in an aminophospholipid/miltefosine transporter (MT) is sufficient to elicit drug resistance, very few naturally miltefosine-resistant (MIL-R)...
10.
Eberhardt E, van den Kerkhof M, Bulte D, Mabille D, Van Bockstal L, Monnerat S, et al.
J Mol Diagn
. 2018 Jan;
20(2):253-263.
PMID: 29355825
Several methods have been developed for the detection of Leishmania, mostly targeting the minicircle kinetoplast DNA (kDNA). A new RNA real-time quantitative PCR (qPCR) assay was developed targeting the conserved...